---
figid: PMC8834417__cells-11-00554-g001
figtitle: 'Influence of the Metabolism on Myeloid Cell Functions in Cancers: Clinical
  Perspectives'
organisms:
- NA
organisms_ner:
- Homo sapiens
- Danio rerio
pmcid: PMC8834417
filename: cells-11-00554-g001.jpg
figlink: /pmc/articles/PMC8834417/figure/cells-11-00554-f001/
number: F1
caption: Myeloid cell intrinsic metabolism. Clinical targeting of a specific metabolic
  pathway regulating immunosuppressive myeloid cell functions is very likely to impact
  other metabolic pathways essential for their protumoral activity. Drugs currently
  used in clinical trials targeting different metabolic pathways are depicted in this
  figure in red. 2DG, 2-deoxyglucose; A2AR, adenosine A2A receptor; ADP, adenosine
  diphosphate; AMP, adenosine monophosphate; AMPK, 5′ adenosine monophosphate-activated
  protein kinase; ATP, adenosine triphosphate ATRA, all-trans retinoic acid; cAMP,
  cyclic adenosine monophosphate; CDDO-Me, bardoxolone methyl; G6P, glucose-6-phosphate;
  Glut, glucose transporter; HIF1α, hypoxia-inducible factor 1-alpha; HK1/2, hexokinase
  1/2; IL-10, interleukin 10; MCT, monocarboxylate transporter; NOX2, NADPH oxidase
  2; O2, dioxygen; PD1, programmed cell death protein 1; ROS, reactive oxygen species;
  TCA, tricarboxylic cycle; TGF-β, transforming growth factor β; TME, tumor microenvironment.
papertitle: 'Influence of the Metabolism on Myeloid Cell Functions in Cancers: Clinical
  Perspectives.'
reftext: Thomas Boyer, et al. Cells. 2022 Feb;11(3):554.
year: '2022'
doi: 10.3390/cells11030554
journal_title: Cells
journal_nlm_ta: Cells
publisher_name: MDPI
keywords: metabolism | myeloid cells | macrophages | myeloid-derived suppressive cells
  | cancer | immunotherapy | immunomodulation | therapeutic strategies
automl_pathway: 0.952781
figid_alias: PMC8834417__F1
figtype: Figure
redirect_from: /figures/PMC8834417__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8834417__cells-11-00554-g001.html
  '@type': Dataset
  description: Myeloid cell intrinsic metabolism. Clinical targeting of a specific
    metabolic pathway regulating immunosuppressive myeloid cell functions is very
    likely to impact other metabolic pathways essential for their protumoral activity.
    Drugs currently used in clinical trials targeting different metabolic pathways
    are depicted in this figure in red. 2DG, 2-deoxyglucose; A2AR, adenosine A2A receptor;
    ADP, adenosine diphosphate; AMP, adenosine monophosphate; AMPK, 5′ adenosine monophosphate-activated
    protein kinase; ATP, adenosine triphosphate ATRA, all-trans retinoic acid; cAMP,
    cyclic adenosine monophosphate; CDDO-Me, bardoxolone methyl; G6P, glucose-6-phosphate;
    Glut, glucose transporter; HIF1α, hypoxia-inducible factor 1-alpha; HK1/2, hexokinase
    1/2; IL-10, interleukin 10; MCT, monocarboxylate transporter; NOX2, NADPH oxidase
    2; O2, dioxygen; PD1, programmed cell death protein 1; ROS, reactive oxygen species;
    TCA, tricarboxylic cycle; TGF-β, transforming growth factor β; TME, tumor microenvironment.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - SLC16A1
  - MCAT
  - MCPH1
  - SLC2A1
  - HK2
  - KCNA5
  - KIF2A
  - KLK2
  - HOOK2
  - HK1
  - KCNA4
  - KLK1
  - HOOK1
  - TAC4
  - PRKAA1
  - PRKAA2
  - PRKAB1
  - PRKAB2
  - PRKAG1
  - PRKAG2
  - PRKAG3
  - HIF1A
  - DECR1
  - MTOR
  - CYBB
  - APRT
  - MFAP1
  - ATP8A2
  - WDTC1
  - PDCD1
  - RPL17
  - SNCA
  - SPATA2
  - RPL17-C18orf32
  - ADORA2A
  - NT5E
  - ENTPD1
  - TGFB1
  - TGFB2
  - TGFB3
  - IL10
  - hk2
  - hk1
  - hif1ab
  - mtor
  - il10
---
